Co-Diagnostics, Inc. (CODX)
| Market Cap | 2.09M -91.2% |
| Revenue (ttm) | 858,888 +69.1% |
| Net Income | -47.48M |
| EPS | -12.86 |
| Shares Out | 7.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,162,439 |
| Open | 0.2453 |
| Previous Close | 0.2778 |
| Day's Range | 0.2453 - 0.2649 |
| 52-Week Range | 0.2450 - 13.5400 |
| Beta | 3.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsNews
Co-Diagnostics Earnings Call Transcript: Q3 2026
Two diagnostic submissions are under regulatory review, alongside progress in India TB testing, blood-based assay feasibility work and Vector Smart deployments. Q3 operating expenses and 9M operating cash use were lower YoY.
Co-Diagnostics Earnings release: Q3 2026
Co-Diagnostics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Co-Diagnostics Quarterly report: Q3 2026
Co-Diagnostics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Co-Diagnostics Reports Third Quarter 2026 Financial Results
Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over Year Platform Capabilities Expanding with ReadyGo Collaboration, India Connectivity a...
Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mol...
Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch
Events in Bali and Rio de Janeiro Bring Together Global Health Leaders to Address Tuberculosis Diagnosis, Treatment and Prevention SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Na...
Co-Diagnostics registers to sell 39.59M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 39.59M shares of common stock. The company is not selling any…
Co-Diagnostics Registration statement: Registration filing
Co-Diagnostics filed a registration statement on November 4, 2026, providing details about a securities offering with the SEC.
Co-Diagnostics JV’s Saragene biopsy test shows efficacy in published study
Co-Diagnostics (CODX) announced the publication of a peer-reviewed study using the Saragene Human Papillomavirus High Risk, or HPV-HR, Test manufactured by CoSara Diagnostics, the company’s joint vent...
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results CoSara to Exhibit at MICROCON 2026, ...
Co-Diagnostics JV completes study of CoSara PCR MTB test, submits for clearance
Co-Diagnostics (CODX) announced that CoSara Diagnostics Pvt, the company’s joint venture in India, has completed its clinical performance study of the CoSara PCR Mycobacterium tuberculosis test on the...
Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026 Study Demonstrated 97.3% Sensitivity and 96.0% Specificity Consistent Performance Across Three Test Batches Integrated M...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
Participation in NUWATIN 2026 to Support Advancement of Strategic Manufacturing, Technology Transfer, and Industrial Localization Initiatives Under Saudi Vision 2030 Invitation Follows Execution of Ma...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague Diagnostics Draws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing ...
Co-Diagnostics to install Vector Smart laboratory for Native American tribe
Co-Diagnostics (CODX) has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. The order represents the comp...
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in house SALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "t...
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseases Company to participate in October 9 Utah Global Health...
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform SALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular ...
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX...
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. De...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...